Consideration of Neuroinflammation in Both Pediatric Acute-Onset Neuropsychiatric Syndrome and “Traditional” Obsessive-Compulsive Disorder Authors: Andy J Chien Published: 2026 Dear Editors, Kazangian et al present a patient with pediatric acute-onset neuropsychiatric syndrome (PANS), a diagnosis that the authors diplomatically characterize as an ongoing subject of debate. 1 The authors should be commended for their willingness to recognize this diagnosis, because it is possible that a deeper discussion and understanding of PANS will further our understanding of obsessive-compulsive disorder (OCD) in general. Emerging evidence suggests that neuroinflammation may underlie OCD cases beyond those meeting PANS criteria. A small study correlated inflammation measured by positron emission tomography (PET) imaging with clinical measurements of OCD severity in patients without known antecedent infection. 2 A genome-based meta-analysis with over 53,000 patients with OCD identified multiple immune-related genes associated with increased OCD risk, suggesting that neuroinflammation may play a role in a wider subset of OCD than just PANS. Several clinical trials reported that the addition of anti-inflammatory agents including celecoxib, naproxen, minocycline, and ondansetron resulted in major improvements in clinical OCD scores in patients who were not classified as PANS. Furthermore, higher rates of OCD have been observed in patients with multiple sclerosis and other autoimmune diseases. These studies support a potential role for neuroimmune processes in OCD pathophysiology, even in cases that are not classified as PANS (see online supplementary file 1). The authors point out that the postinfectious, neuroinflammation-based diagnosis of PANS should be considered in cases of abrupt-onset OCD because proper recognition can influence diagnostic workup and treatment compared with traditional OCD without neuroinflammation. However, this patient was treated with fluoxetine and cognitive behavioral therapy, which is standard treatment for OCD that is not classified as PANS. Although the authors reference a summary statement from the American Academy of Pediatrics, 3 they make no reference to the multidisciplinary PANS Research Consortium and their consensus recommendations developed by a multidisciplinary panel of neuroinflammation experts that includes psychiatrists. 4 Although the PANS Research Consortium guidelines would classify this patient as moderate-to-severe and warranting further immunomodulatory consideration, 4 it is unclear whether anti-inflammatory treatment was considered for this patient despite the authors favoring the diagnosis of PANS over traditional OCD. Patients with PANS demonstrate an increased sensitivity to psychotropic medications, with intolerable reactions occurring at doses lower than standard starting doses recommended for OCD. 5 It is unclear if the diagnosis of PANS guided the authors in their dosing of fluoxetine. Finally, although this case report was meant to provide an example of value-based care, it seems premature to declare success in this case given the relapsing nature of both PANS and non-PANS OCD. This case report provided a starting point for discussions on shared features with PANS and classical pediatric OCD as well as the possible role of anti-inflammatory treatment. Given the number of both pediatric and adult patients affected by OCD, further studies may eventually discover that a value-based approach to these patients should include more rigorous investigation and treatment, not less. Conceivably, the long-term cost of missing a treatable inflammatory etiology could easily exceed the cost of what the American Academy of Pediatrics currently recommends in their limited value-based framework. Supplementary Material online supplementary file 1: